An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
BioViva announced it has been granted a U.S. patent for a gene therapy approach that combines two genes, hTERT and follistatin-344, aimed at treating disorders linked to aging. In plain terms, the company says the patent covers a method of delivering these two genetic instructions into the body to try to counter some effects of getting older. This is a patent — a legal right to exclude others from using that specific approach — not proof the treatment works in people. hTERT is the gene that makes telomerase, an enzyme tied to the ends of chromosomes called telomeres. Telomeres shorten as cells divide, and very short telomeres are associated with aging and some diseases. Follistatin-344 is a form of a protein that can block molecules that limit muscle growth, so it’s been studied for muscle wasting and similar conditions. Together, the idea is to both protect cellular “clock” structures and support muscle health. Saying this is “gene therapy” means the plan is to deliver the genes into cells so the body makes these proteins itself. The news here is about a patent grant, not a new clinical trial or big human study. The announcement doesn’t, by itself, show safety or that people will benefit. Often companies file patents based on preclinical work (lab or animal studies) or on a proposed method. If you look for evidence of actual human benefit, you’d need published clinical trials showing that giving these genes improves health outcomes and is safe. The snippet doesn’t report such trials or results, so the effect size and real-world impact remain unknown. Why this matters: patents can be important milestones for biotech firms because they protect intellectual property and can attract investment or partners. For patients and the public, the idea of therapies that target basic aging mechanisms is appealing because it could, in theory, address multiple age-related problems instead of one disease at a time. Investors may pay attention; researchers may see the patent as a sign of which approaches companies are prioritizing. But a patent alone doesn’t change medical practice or mean a treatment will be available. There are important caveats and risks. Gene therapies can have serious side effects, and long-term risks—especially for interventions affecting cell division or growth—need careful study. Altering telomerase activity has theoretical links to cancer risk because it can allow cells to divide more than they normally would; that’s one reason claims around hTERT need rigorous safety data. Regulatory approval requires well-controlled human trials demonstrating safety and benefit; a patent is only an early step. People should not try unproven gene therapies offered outside clinical trials. Bottom line: BioViva’s patent shows a company is pursuing a specific gene therapy idea combining hTERT and follistatin-344, but it’s a legal protection, not proof that the approach is safe or effective in people.
Source: Morningstar